Drug Trial Radar · NCT04702776
Study to Compare the Efficacy of the Ophthalmic Solution Humylub Ofteno® PF With Hyabak® and Lagricel Ofteno® PF as Treatment for Dry Eye.
Last checked: Nov 20, 2026Latest source record: Feb 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
182
Actual
Start
Dec 9, 2021
Primary completion
May 15, 2023
Study completion May 15, 2023
Sponsor
- Lead sponsor
- Laboratorios Sophia S.A de C.V.Industry
- Sponsor type
- Industry
- First posted
- Jan 11, 2021
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Phase IV, non inferiority, controlled, open, multicenter clinical study to compare the efficacy of the Ophthalmic Solution Humylub Ofteno® PF against Hyabak® and Lagricel Ofteno® PF applied quater in die (QID) for 30 days in patients with mild to moderate dry eye disease.
Conditions
- Dry Eye
Interventions
Sodium hyaluronate 0.1%/chondroitin sulfate 0.18%Drug
Application of one drop of Humylub Ofteno® PF (Sodium hyaluronate 0.1%/chondroitin sulfate 0.18%) QID in both eyes (OU) during 30 days.
Sodium hyaluronate 0.15%Drug
Application of one drop of Hyabak® PF (Sodium hyaluronate 0.15%) QID in OU during 30 days.
Sodium hyaluronate 0.4%Drug
Application of one drop of Lagricel Ofteno® PF (Sodium Hyaluronate 0.4%) QID in OU during 30 days.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change in Ocular Surface Disease Index (OSDI)Time frame: Days: 0 (± 2) (eligibility visit), 17 - 19 (± 1) (first follow-up visit), and 31 - 33 (± 1) (final visit).
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Unidad Clínica de Bioequivalencia, S. de R.L. de C.V.
Guadalajara, Jalisco, Mexico
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.